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Abstract 
Autologous stem cell transplantation is still
considered  the  standard  of  care  in  young
patients  with  multiple  myeloma  (MM).  This
disease  is  the  most  common  indication  for
high-dose  therapy  (HDT)  supported  by
hematopoietic  stem  cell  transplantation  and
much data support the benefit of this proce-
dure.  Results  of  randomized  studies  are  in
favor  of  tandem  autologous  transplantation
although  the  effect  on  overall  survival  is
unclear. Based on sequential registration trials
in the Nordic area, we aimed to evaluate the
outcome of conventional single or double HDT.
During 1994-2000 we registered a total of 484
previously untreated patients under the age of
60 years at diagnosis who on a regional basis
initially were treated with single [Trial NMSG
#5/94  and  #7/98  (N=383)]  or  double  [Trial
Huddinge  Karolinska  Turku  Herlev  (N=101)]
high-dose melphalan (200 mg/m
2) therapy sup-
ported by autologous stem cell transplantation.
A complete or very good partial response was
achieved by 40% of patients in the single trans-
plant group and 60% of patients in the double
transplant group (p=0.0006). The probability of
surviving progression free for five years after
the diagnosis was 25% (95% CL 18-32%) in the
singletransplant group and 46% (95% CL 33-
55%)  in  the  double  transplant  group
(p=0.0014).  The  estimated  overall  five-year
survival rate was 60% in the single transplant
group  and  64%  in  the  doubletransplant
(p=0.9). In a multivariate analysis of variables,
including single versus double transplantation,
β2 microglobulin level, age, sex and disease
stage, only β2 microglobulin level was predic-
tive for overall survival (p>0.0001) and pro-
gression  free  survival  (p=0.001).  In  accor-
dance  with  these  results,  a  1:1  case-control
matched comparison between double and sin-
gle transplantation did not identify significant
differences in overall and progression free sur-
vival.
In this retrospective analysis up frontdouble
transplantation  with  melphalan  (200  mg/m
2)
as compared to single transplantation did not
seem  to  improve  the  final  outcome  among
patients in the Nordic area. These data are in
accordance with recent publications from the
Bologna 96 trial indicating that a second trans-
plant should not be recommended up front as
standard care.
Introduction
Multiple myeloma (MM) is the second most
common  hematologic  cancer  after  non-
Hodgkin's  lymphoma.  More  than  50,000
patients in Europe alone have MM and about
half  of  these  patients  are  diagnosed  when
they are younger than 65 years of age, and
increasingly detected under the age of 40.
Today, MM is the most common indication
for high-dose therapy supported by hemato-
poietic stem cell transplantation in the world,
and more data support the benefit of this pro-
cedure.  These  remarkable  results  radically
altered the disease management in patients
below 65 years of age. Thus, stem cell trans-
plantation has been recommended for these
patients as part of the initial therapy or at the
time  of  disease  progression.  However,  the
median  duration  of  response  is  short  and
almost all patients ultimately relapse.
1-9
The InterGroupe Francophone du Myélome
(IFM) took the next logical step and asked if
the  combination  of  two  cycles  of  high-dose
therapy and hematopoietic stem cell rescue
might improve survival. The group assigned
399  patients  with  untreated  MM  below  60
years of age to receive VAD (vincristine, adri-
amycin  and  dexamethasone)  as  induction
therapy  and  afterwards  assigned  these
patients randomly to single or double trans-
plantation  conditioned  by  melphalan  140
mg/m
2 and TBI (standard single transplanta-
tion) or melphalan 140 mg/m
2 followed by 140
mg/m
2 and  TBI  (experimental  double  trans-
plantation).
10 Following a median observation
of approximately six years, response rates in
the two groups were not significantly differ-
ent, but the probabilities of event free survival
and  overall  survival  were  prolonged  with  a
double transplant benefit that had not been
evident  in  early  analyses.
10 This  important
study demonstrates that double transplanta-
tion is one of the options for treating myelo-
ma, particularly those younger than 60 years
of age who have a suboptimal response to a
single transplant. 
However, the IFM study has raised a num-
ber of questions. First and most important, do
the beneficial responses in the double trans-
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melphalan? In other words, is a single trans-
plant  with  the  use  of  maximally  tolerated
doses of melphalan (200 mg/m
2) as effective
as a double transplantation strategy with the
high dose of melphalan administrated twice?
Second, what should be recommended, as
only  one  of  several  phase  II-III  studies  has
documented an effect on overall survival?
11,12
Without doubt the IFM study has to be con-
sidered the Proof of Principle but in the light
of  the  study  design,  as  well  as  the  overall
results from other studies, it is still unknown
if a second transplant should be recommend-
ed in all cases, even if the response to the first
transplant has been inferior.
In this unclear situation we now see alter-
native  progress  in  the  treatment  of  MM  by
new drugs currently being analyzed in ran-
domized  trials.  In  the  near  future,  ongoing
studies  will  clarify  the  role  of  these  novel
agents, including thalidomide and its analogs,
and bortezomib etc., in the context of autolo-
gous stem cell transplantation. However, trial
designs including consolidation therapy such
as that planned by the NMSG may be ham-
pered by a double autologous transplantation
strategy, not yet documented to have an effect
on survival. Here the Nordic group reports the
data analysis of a total of 484 MM patients
transplanted from 1994-2000 including double
transplantation of 101 patients. The conclu-
sions are based on results from two sequen-
tial  phase  II  trials  evaluating  double  trans-
plantation  in  4  selected  centers  (Huddinge,
Karolinska, Turku and Herlev) by comparing
the outcome with data from 383 single trans-
planted patients included in trial NMSG #5/94
and #7/98 from the other centers.
1,13,14
Design and Methods
Approval and patient eligibility
The scientific protocols were reviewed and
approved by the regional ethics committees in
Denmark, Sweden, Finland and Norway, and
all  patients  gave  written  informed  consent
before study entry. Patients less than 60 years
of age who had Durie-Salmon stage I with at
least one bone lesion, II, or III myeloma were
eligible. The criteria for exclusion were prior
treatment  for  myeloma,  another  cancer,
abnormal cardiac function, chronic respirato-
ry disease, abnormal liver function or psychi-
atric disease.
Design and aims of the program
This study was planned to include previous-
ly untreated patients under the age of 60 years
at diagnosis who on a regional basis initially
were treated with single [Trial NMSG #5/94
and #7/98 (N=383)] or double [Trial HKTH
(N=101)] high-dose melphalan (200 mg/m
2)
therapy  supported  by  autologous  stem  cell
transplantation. The aim was to evaluate the
outcome of conventional single or double HDT.
Double transplant study population: HKTH 
From  June  1994-June  2000,  101  patients
with  newly  diagnosed  myeloma  <60  years
were entered into a phase II trial evaluating
double  high-dose  melphalan  (200  mg/m
2)
therapy  with  autologous  stem  cell  support.
This  included  patients  from  Huddinge  and
Karolinska Hospitals in Stockholm, Sweden,
Turku  University  Hospital  in  Finland,  and
from  June  1997  Herlev  University  Hospital,
Copenhagen in Denmark. This trial covered a
population of 3 million. The number of new
cases of myeloma <60 years in this population
during the study period was estimated to be
200 patients.
Single transplant population NMSG
#5/941 and NMSG #7/9814 NMSG #5/94
From  March  1994  until  June  1997,  122
Swedish patients with newly diagnosed myelo-
ma <60 years were entered into NMSG #5/94
trial evaluating one cycle of high-dose melpha-
lan therapy with autologous stem cell support.
One hundred and seven of these were treated
according to the specified treatment protocol
and received single transplantation. This trial
covered a population of 15 million. A total of
348 Nordic patients were reported to the study
secretariat. The expected number of new cases
of myeloma <60 years in this population dur-
ing the study period was estimated to be 450.
In  this  trial,  a  highly  significant  survival
advantage was found for high-dose melphalan
therapy, with a prolongation of the median sur-
vival from 44 to 62 months.
1
NMSG #7/98
From  January  1998  until  June  2000,  452
patients <65 years were registered in a similar
trial  evaluating  high-dose  melphalan  with
autologous  stem  cell  support,  and  using  a
matched historical patient group as control. Of
these,  276  Swedish,  Norwegian  and  Danish
patients aged <65 years were treated accord-
ing  to  the  specified  treatment  protocol  and
received single transplantation. This trial also
covered a population of 15 million. A total of
452 patients were reported to the study secre-
tariat. The number of expected new cases of
myeloma <65 years in this population during
the study period was estimated to be 580. The
main purpose of this study was to evaluate the
impact  of  high-dose  melphalan  therapy  in
patients  aged  60-64  years  in  a  population-
based study. Age was found to influence out-
come after intensive therapy, which, however,
prolonged  survival  but  with  less  superiority
than in younger patients.
14
Treatment plan
All patients could be treated according to the
protocol provided that they were not consid-
ered ineligible for the induction therapy. The
treatment was divided into 4 phases: (I) induc-
tion  therapy;  (II)  peripheral  blood  stem  cell
harvest; (III) high-dose therapy with single or
double high-dose melphalan 200 mg/m
2 given
as  a  single  dose  intravenously,  followed  by
stem  cell  transplantation  and  (IV)  follow-up
(described in details in 1). Patients with pro-
gressive disease or with emerging contraindi-
cations to phases II to III were taken off the
treatment protocol.
Diagnostic criteria 
The diagnosis of MM was accepted if crite-
ria A+C, A+D, or B+C+D of the following were
fulfilled:  (A)  serum  monoclonal  component
(M-protein) concentration of immunoglobulin
(Ig)G > 30 g/L, IgA > 20 g/L, the presence of an
M-protein of IgD or IgE regardless of concen-
tration, or Bence-Jones proteinuria > 1 g/24 h;
(B) M-protein in serum or urine at a lower
concentration than described under A; (C) at
least 10% plasma cells in bone marrow aspirate
or biopsy-verified plasmacytoma of bone or soft
tissue; and (D) osteolytic bone lesions. Only
patients with symptomatic disease were regis-
tered.
Criteria for response
Complete response was defined as the dis-
appearance of M-protein from serum and urine
in agarose gel electrophoresis and < 5% plas-
ma cells in a bone marrow aspirate. Very good
partial remission (VGPR) was 90-99% reduc-
tion of M-protein. Partial response was defined
by at least a 50% reduction of the initial serum
M-protein  concentration  and  a  reduction  of
Bence-Jones proteinuria to <0.2 g/24 h. Minor
response was defined by a 25-50% reduction of
the initial serum M-protein concentration and
a reduction in Bence-Jones proteinuria by at
least 50% but exceeding 0.2 g/24 h.
No statistically significant differences were
observed between the groups at any stage of
the treatment with regard to these compar-
isons. To fulfill the criteria for complete, par-
tial, or minor response, the patients were not
allowed to have any other signs of myeloma
progression, such as persisting hypercalcemia
or  progressive  renal  insufficiency,  skeletal
disease, or bone marrow insufficiency due to
plasma  cell  infiltration.  Progression  was
defined by a confirmed increase in the serum
M-protein  concentration  by  more  than  25%
from the level at the time of best response, an
increase of Bence-Jones proteinuria to more
than 1.0 g/24 h, or other unequivocal signs of
disease progression, such as hypercalcemia,
progressive  skeletal  disease,  or  soft-tissue
plasmacytoma.  Progression,  death  without
progression,  and  occurrence  of  a  secondary
malignancy  were  all  considered  as  events.
Event free and overall survival was calculated
from the start of therapy.
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All registered patients were followed until
death. Patients were evaluated before the start
of phase II and phase III, and thereafter every
sixth week. 
Statistical analysis
All analyses were performed on treatment
received  basis  and  are  not  an  intention-to-
treat study. The proportions of patients with a
given  characteristic  were  compared  using
Fisher's exact test for variables with frequency
scale  and  Wilcoxon  rank-sum  test  for  the
remaining  variables.  Event  free  and  overall
survival rates were calculated according to the
Kaplan-Meier  method,  and  survival  compar-
isons between groups were made by the log-
rank  test.  The  Cox  proportional  hazards
regression  model  was  used  to  estimate  the
prognostic  importance  of  different  variables.
Age, bone marrow plasma cells, blood hemoglo-
bin, serum calcium, serum creatinine, blood
platelets, and serum albumin were included as
continuous variables. The following variables
were  dichotomized:  sex  (male  vs. female),
stage according to Durie and Salmon (I or II vs.
III),  M-protein  class  (IgG  vs. other;  IgA  vs.
other; light chains only vs.other), and osteolyt-
ic bone lesions (none vs. limited or advanced).
In the multivariate analyses, forward stepwise
variable selection was used.
Results
Baseline characteristics at diagnosis
Table  1  shows  the  base-line  clinical  and
demographic  characteristics  of  the  484
patients entering this analysis. There were no
differences between the treatment groups but
for disease stage.
Response rates in the collaborative
trials
Following  the  final  preparative  treatment
with high-dose melphalan and autologous stem
cell transplantation, the overall rates of com-
plete or very good partial response for patients
who actually received a single or a double trans-
plant (Table 2) were in the collaborative trials
60% and 40%, respectively (p=0.0006).
The survival outcome
In the single transplant group, the median
follow-up was 34 months (range, 12-115) from
the time of transplantation. The median dura-
tions of event free, progression free, and over-
all survival were 33, 33, and 78 months, respec-
tively.  The  estimated  probabilities  of  event-
free, progression free, and overall survival five
years  after  inclusion  were  25%  (Figure  1a),
26%, and 60% (Figure 1b), respectively. Of the
96 deaths in this group, 85% were attributed to
progressive myeloma, 2% related to the trans-
plantation procedure. In the double transplant
group, the median follow-up was 48 months
(range, 10-108) from the time of transplanta-
tion. The median durations of event free, pro-
gression free, and overall survival were 46, 46,
and  76  months,  respectively.  The  estimated
probabilities  of  event-free,  progression  free,
and overall survival five years after the inclu-
sion  were  44%  (Figure  1a),  45%,  and  64%
(Figure 1b), respectively. Of the 33 deaths in
this group, 61% were attributed to myeloma,
while 3% were related to the transplantation
procedure. As compared with single transplan-
tation, double transplantation improved pro-
gression free survival (p=0.001) (Figure 1b)
whereas overall survival was similar (p=0.9)
(Figure 1a). 
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Table 1. Base-line characteristics of the patients according to treatment group.
Variable Double transplantation Single transplantation p-value
N 101 383
Age* 55 years 54 years 0.4
#
Sex (female, male) 44/57; (44 and 56%) 151/232; (39 and 61%) 0.5
§
β2 microglobulin* 2.8 mg/L 3.4 mg/L 0.1
#
Stage I/II/III 12/23/64; (12, 23 and 65%) 16/108/259; (4, 28 and 67%) 0.015
§
*Median values; 
#Mann-Whitney test; 
§Fisher’s exact test.
Table 2. Comparison between double and single transplantation.
Variable Double transplantation Single transplantation p-value
N (data/missing) 101 (98/3) 383
CR 56 (57%) 139 (36%) 0.003
§
CR + VGPR 59 (60%) 155 (40%) 0.0006
§
OS % censored See Figure 1a See Figure 1a 0.9
*
OS median (years) 6.3 6.5
PFS % censored See Figure 1b See Figure 1b 0.0014
*
PFS median (years) 3.8 2.7
#Mann-Whitney test; 
§Fisher’s exact test; 
*Log rank test (See Figure 1a and b)
Figure 1. Overall survival (a) and progression free survival (b) following double trans-
plantation in trial HKTH (N=101), compared to single transplantation in NMSG #5/94
plus #7/98 (N=384). The estimated probabilities are shown for double (DTx) and single
(STx) transplantation. Tables below the graph indicate patients at risk for the estimate.
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p = 0.9Analysis for prognostic variables
In a multivariate analysis of all 484 patients
(Table 3), overall survival was significantly relat-
ed to baseline serum levels of β2 microglobulin
(p<0.0001) but not to the maximal response to
treatment (p=0.2), not to age (p=0.5), disease
stage or treatment assignment (p=0.4). 
Case control study comparing double and
single transplantation 
To illustrate the impact of β2 microglobulin,
each  double  transplanted  patient  from  the
study group was matched with one case of a
single transplanted patient (N=101) from the
corresponding  NMSG  database,  according  to
β2 microglobulin, age, sex and disease stage
in this order. The results are shown in Figure
2 and document no survival benefit.
Treatment-related toxicity
The hematopoietic reconstitution was rec-
ognized  to  be  similar  in  the  two  groups  as
expected.
13 There  were  2  (0.5%)  treatment-
related deaths in the single transplant group of
383 patients and 3 (3.0%) in the double trans-
plant group of 101 patients (p=0.06).
Minimal residual disease
In the double transplant group, the number
of  bone  marrow  malignant  plasma  cells  2-3
months post high-dose therapy was estimated
by conventional recommended flow cytometry
and  revealed  no  significant  differences
between the levels following the first and the
second transplant. The median level of plasma
cells was 0.22% and 0.16%, respectively (N=17;
p=0.3).
Discussion
Double  autologous  transplantation  regi-
mens have been used to treat myeloma for the
past decade, although the advantage over sin-
gle  transplantation  is  unclear.  Despite  the
favorable results reported by IFM,
10 it remains
the case that progressive myeloma will develop
in almost 80% of patients within seven years
after they have undergone double transplanta-
tion. This unclear situation is further extend-
ed by progress in the number of new drugs cur-
rently being analyzed in randomized trials. In
the near future, ongoing studies will clarify the
role  of  inflammatory  mediators  and  protea-
some inhibitors in the context of autologous
stem  cell  transplantation.  However,  trial
design  including  consolidation  therapy  with
new  drugs  may  be  hampered  by  the  biased
double  autologous  transplantation  up  front
strategy which has not yet been documented to
have an effect on overall survival.
11-12 Among
the patients enrolled in the double transplant
group  in  the  present  study,  23%  could  not
receive their assigned second transplantation
and have not been included in this analysis.
This number is in accordance with the litera-
ture.
10 The most common reasons were a deci-
sion for allogeneic transplantation, poor per-
formance status, and poor stem cell collection
owing  to  an  insufficient  response  after  the
initial VAD treatment.
The  risk  of  life-threatening  toxic  effects
due  to  double  transplantation  was  a  major
concern. However, the hematopoietic recon-
stitution was similar after one or two trans-
plantations
13 but the rates of death caused by
toxic effects were increased in the IFM study.
Analysis of the present phase II trials after
a median follow-up period of 3-4 years docu-
mented significant improved response rates
Article
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Table 3. Statistical analysis of variables on overall (OS) and progression free survival.
OS Univariat Multivariat
Variables  RR (95% CI) p-value RR (95% CI) p-value
Single vs. double transplantation 1.0 (0.7-1.5) 0.9 0.8 (0.5-1.3) 0.4
(Log) β2 microglobulin 1.8 (1.5-2.2) < 0.0001 1.8 (1.4-2.2) < 0.0001
Age 1.02 (0.99-1.05) 0.3 1.02 (0.99-1.05) 0.3
Sex (Male vs. female) 1.3 (0.9-1.8) 0.1 1.2 (0.8-1.8) 0.4
Stage I, II or III - 0.3 NI NI
Stage (II, III vs. I) 2.1 (0.8-5.6) 0.1 1.5 (0.5-5.0) 0.4
Response non-CR vs. CR 1.3 (0.9-1.8) 0.2 NI NI
PFS Univariat Multivariat (N=380)
Variables  RR (95% CI) p-value RR (95% CI) p-value
Single vs. double transplantation 1.7 (1.2-2.3) 0.0009 1.3 (0.9-1.9) 0.1
(Log) β2 microglobulin 1.3 (1.1-1.6) 0.0006 1.3 (1.1-1.6) 0.001
Age 1.00 (0.98-1.02) 0.9 1.01 (0.98-1.03) 0.6
Sex (Male vs. female) 1.2 (0.9-1.6) 0.1 1.2 (0.9-1.6) 0.2
Stage I, II or III  - 0.06 NI NI
Stage (II, III vs. I) 2.0 (1.0-3.9) 0.02 1.3(0.6-2.8) 0.5
Response non-CR vs. CR 1.9 (1.4-2.4) < 0.0001 NI NI
NI, Variable not included in multivariate analysis
Figure 2. Case control analysis comparing double and single transplantation. Overall sur-
vival  (a)  and  progression  free  survival  (b)  following  double  transplantation  in  trial
HKTH was compared to 101 case controlled single transplantations in NMSG #5/94
plus #7/98. The estimated probabilities are shown for double (DTx) and single (STx)
transplantation. Tables below the graph indicate patients at risk for the estimate.
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